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If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate. Cardioversion of symptomatic atrial fibrillation (AF) is commonly used to restore sinus rhythm, both acutely and as part of a long-term rhythm control strategy.(1) This approach is associated with a risk of stroke, however the efficacy of direct oral anticoagulants (DOACs) compared to vitamin K antagonists (VKA) for prevention of thromboembolism is unclear. We performed a meta-analysis of trials that have randomized AF patients undergoing cardioversion to DOAC or VKA. An online search was performed of PubMed and the Cochrane library, in addition to manual screening. We used an intention-to-treat approach with a fixed-effects model. Our aim was to provide clinicians with a clear understanding of which anticoagulation strategy provides the safest outcome for AF patients undergoing cardioversion.
The search identified 124 studies, of which three prospective trials met inclusion criteria. (2) (3) (4) In total, 5203 patients were included in this analysis, 2850 randomized to DOAC and 2353 to VKA.
Mean age was 65 years (SD 11), female patients accounted for 32%, and the CHA 2 DS 2 -VASc score was ≥2 in over 70% of patients. All three trials required treatment with the allocated anticoagulant prior to cardioversion, and in VKA patients, parenteral heparin was used to bridge warfarin therapy until an international normalized ratio ≥2.0 was achieved. Around half of patients had early cardioversion guided by imaging (mainly transesophageal echocardiography). Study treatment after cardioversion was continued for 28-42 days, with 30-day safety follow-up. The risk of bias in these trials was low, apart from potential performance bias due to the open-label designs.
Primary outcome: The composite of stroke, systematic embolism, myocardial infarction and cardiovascular death occurred in 12/2850 (0.42%) patients randomized to a DOAC versus 23/2353 (0.98%) to VKA (Figure) . DOAC therapy considerably reduced primary outcome events compared to VKA, with a pooled risk ratio of 0.42, 95% CI 0.21-0.86, a p-value of 0.017, and no heterogeneity between trials (I 2 =0%, p=0.84).
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Secondary outcomes: Stroke and systemic embolism occurred in 5/2850 (0.18%) in DOAC patients versus 13/2353 (0.55%) randomized to VKA; the pooled risk ratio was 0.33, 95% CI 0.12-0.91, with a p-value of 0.032 and no heterogeneity between trials (I 2 =7.5%, p=0.34). There were no significant differences between NOAC and VKA in all-cause mortality (risk ratio 0.58, 95% CI 0.22-1.52, p=0.27) or major bleeding (risk ratio 0.61, 95% CI 0.28-1.34, p=0.22), however both point estimates were consistent with the benefit seen for other outcomes (Figure) . This meta-analysis is limited by the nature of the trials included, which only studied the short-term effects of anticoagulation. None of the trials were individually powered for clinical outcomes, although the power for our pooled analysis was >0.99 for the stroke-related composite outcomes.
Over 90% of patients underwent electrical cardioversion, and although there is no a priori reason to suspect a difference with pharmacological cardioversion, data in this context are scarce. Further studies are needed to address the remaining gaps in evidence, including the identification of those at risk of adverse events despite oral anticoagulation, and the optimal timing of both anticoagulants and cardioversion to minimize stroke risk. In combination with integrated approaches to AF care and stratification of therapy (5) , the routine use of DOACs for cardioversion can improve safety for patients undergoing cardioversion.
Figure: Meta-analysis of DOAC versus VKA for cardioversion of AF

